INDP vs. SLGL, AYTU, GLTO, COCP, VBIV, GLYC, KALA, NRBO, BIVI, and NERV
Should you be buying Indaptus Therapeutics stock or one of its competitors? The main competitors of Indaptus Therapeutics include Sol-Gel Technologies (SLGL), Aytu BioPharma (AYTU), Galecto (GLTO), Cocrystal Pharma (COCP), VBI Vaccines (VBIV), GlycoMimetics (GLYC), KALA BIO (KALA), NeuroBo Pharmaceuticals (NRBO), BioVie (BIVI), and Minerva Neurosciences (NERV). These companies are all part of the "pharmaceutical preparations" industry.
Sol-Gel Technologies (NASDAQ:SLGL) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, community ranking, dividends, earnings, institutional ownership and analyst recommendations.
Indaptus Therapeutics has lower revenue, but higher earnings than Sol-Gel Technologies. Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Sol-Gel Technologies, indicating that it is currently the more affordable of the two stocks.
Sol-Gel Technologies presently has a consensus price target of $6.50, suggesting a potential upside of 821.99%. Indaptus Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 412.82%. Given Indaptus Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Sol-Gel Technologies is more favorable than Indaptus Therapeutics.
Indaptus Therapeutics has a net margin of 0.00% compared to Indaptus Therapeutics' net margin of -1,331.01%. Indaptus Therapeutics' return on equity of -61.52% beat Sol-Gel Technologies' return on equity.
Sol-Gel Technologies received 138 more outperform votes than Indaptus Therapeutics when rated by MarketBeat users. However, 83.33% of users gave Indaptus Therapeutics an outperform vote while only 63.25% of users gave Sol-Gel Technologies an outperform vote.
In the previous week, Sol-Gel Technologies had 4 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 4 mentions for Sol-Gel Technologies and 0 mentions for Indaptus Therapeutics. Sol-Gel Technologies' average media sentiment score of 0.00 beat Indaptus Therapeutics' score of -0.50 indicating that Indaptus Therapeutics is being referred to more favorably in the news media.
Sol-Gel Technologies has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500.
26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by company insiders. Comparatively, 29.5% of Indaptus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Sol-Gel Technologies beats Indaptus Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Indaptus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Indaptus Therapeutics Competitors List
Related Companies and Tools
